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Abstract 
Objective: Fat content and volume of liver and pancreas are associated with risk of diabetes 
in observational studies; whether these associations are causal is unknown. We conducted 
a Mendelian randomization (MR) study to examine causality of such associations. 
Research design and methods: We used genetic variants associated (p < 5×10−8) with the 
exposures (liver and pancreas volume and fat content) using MRI scans of UK Biobank 
participants (n=32,859). We obtained summary-level data for risk of type 1 (9,358 cases) 
and type 2 (55,005 cases) diabetes from the largest available genome-wide association 
studies. We performed inverse-variance weighted MR as main analysis and several 
sensitivity analyses to assess pleiotropy and to exclude variants with potential pleiotropic 
effects.  
Results: Observationally, liver fat and volume were associated with type 2 diabetes (odds 
ratio (OR) per one standard deviation (SD) higher exposure 2.16 [2.02 - 2.31] and 2.11 
[1.96, 2.27], respectively). Pancreatic fat was associated with type 2 diabetes (1.42 [1.34, 
1.51]) but not type 1 diabetes, and pancreas volume was negatively associated with type 1 
diabetes (0.42 [0.36, 0.48]) and type 2 diabetes (0.73 [0.68, 0.78]). MR analysis provided 
evidence only for a causal role of liver fat and pancreas volume on risk of type 2 diabetes 
(1.27 [1.08,1.49] or 27% increased risk and 0.76 [0.62,0.94] or 24% decreased risk per 1SD, 
respectively) and no causal associations with type 1 diabetes. 
Conclusions: Our findings assist in understanding the causal role of ectopic fat in the liver 
and pancreas and of organ volume in the pathophysiology of type 1 and 2 diabetes. 
Introduction 
The pancreas and the liver play key roles in the pathogenicity of both type 1 and type 2 
diabetes in the context of beta cell dysfunction (1) and insulin resistance (2). Studies using 
autopsies, ultrasound (US), computed tomography (CT), and magnetic resonance imaging 
(MRI) have provided three main observations by comparing the levels of liver and pancreas 
fat deposition and volume between individuals with and without diabetes. First, individuals 
with type 1 (3) and type 2 diabetes (4) have smaller pancreases compared to healthy 
controls. Second, pancreatic fat is higher in people with type 2 diabetes compared with age-
matched controls (5) and is negatively associated with insulin secretion (6). Third, 
accumulation of fat in the liver has been linked to resistance to insulin-mediated 
gluconeogenesis and development of type 2 diabetes (7). 
These observations might be confounded by some unknown factors and therefore may not 
concur with the causal nature of the associations. These limitations can be avoided by using 
Mendelian randomization (MR) analysis given the assumptions are met. MR is a method that 
uses genetic variants reliably associated with exposures of interest to estimate a non-
confounded causal association between the exposure (e.g. pancreatic fat) and an outcome 
(e.g. type 2 diabetes) (8). Since allelic variants remain stable over time, their lifetime effects 
on the exposure levels precede the outcome and limit bias from reverse causation. 
Understanding the exact role of liver and pancreas in diabetes risk may be helpful to develop 
more effective prevention, prediction, and treatment, or to supplement existing 
pathophysiological knowledge on important conditions. MRI is an indispensable and non-
invasive tool enabling for the measurement of liver and pancreas and advances in its 
automated analysis has made its measurement at scale a reality (9). The availability of MRI 
scans of liver fat in 32,859 UK Biobank participants has allowed us to understand the 
genetic contribution to variation in fat content and volume of liver and pancreas (9).  
In this study, we aimed to measure the volume and fat content of the liver and pancreas in a 
large cohort of individuals with type 1 and 2 diabetes and use the largest available samples 
with genetic association results to test the causal role of liver and pancreas fat content and 
volume in the etiology of type 1 and type 2 diabetes using MR approach.  
Research Design and Methods 
 
Data Sources and Study Participants 
 
The UK Biobank Study. We used data from the UK Biobank for the MRI study of liver and 
pancreas volume and fat content (10). For the current study, we included 32,859 individuals 
of white British ancestry who underwent the MRI imaging scan. Type 1 and type 2 diabetes 
were defined as binary outcomes from ICD-9 and ICD-10 medical billing codes. The UK 
Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) 
(http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this 
study.  
 
Image processing. The methods have been described in detail elsewhere (9). In 
preprocessing, we blended the six separate Dixon neck-to-knee acquisitions, applying bias 
field correction and automated correction of fat/water swaps. We used the PRESCO 
algorithm to estimate proton density fat fraction (PDFF) in the liver and pancreas multiecho 
slices. To segment organs, we manually annotated organs on the 3D Dixon neck-to-knee 
acquisition (liver) and T1-weighted 3D pancreas acquisition (pancreas). Annotations were 
manually inspected to ensure accuracy before use in modelling. We trained a modified U-net 
convolutional neural network on each modality, and applied this to data from all participants. 
We estimated volumes by counting voxels and multiplying by the size of each model.  
 
GWAS of type 1 and type 2 diabetes. Summary-level association results were extracted 
from the largest publicly available GWAS of type 1 diabetes from the meta-analysis of 9,358 
case and 15,705 controls (11) and type 2 diabetes from a recent meta-analysis of 55,005 
cases and 400,308 controls of European ancestry (12). The UK Biobank participants were 
not part of these GWAS. Details on the demographics of the cohorts participating can be 
found in the respective publications. 
 
FinnGen study. We used GWAS summary statistics from FinnGen (13) to validate our 
findings. The GWAS of type 1 diabetes included 2,649 cases and 183,674 controls, and the 
GWAS of type 2 diabetes included 29,166 cases and 183,185 controls. The definitions of 




We used genetic variants associated with four different exposures, including liver and 
pancreas fat content and volume. The GWAS has been described elsewhere (9) but in 
summary, we included participants who self-reported their ancestry as ‘White British’ and 
who clustered with this group in a principal components analysis. We used BOLT-LMM and 
included age at imaging visit, age squared, sex, imaging centre, scan date, scan time, and 
genotyping batch as fixed-effect covariates, and genetic relatedness as a random effect to 
control for population structure and relatedness.  
 
For each instrument, we used independent variants associated (p<5x10−8) with each 
exposure in the UK Biobank. This included 10 variants associated with liver fat (explained 
4.6% of the observed variance), 11 variants associated with liver volume (2%), 9 variants 
associated with pancreas fat (1.9%), and 17 variants associated with pancreas volume 
(2.3%) (supplementary table 2a) (14). The minor allele frequencies of these variants 
ranged between 0.013 and 0.495. 
 
We extracted estimates of these variants on risk of type 1 (11) and type 2 diabetes (12) 
(supplementary table 2). For genetic variants not present in these GWAS, we selected 
proxy SNPs in linkage disequilibrium (LD, r2 > 0.7) using all European populations from 1000 
Genomes phase 3, HapMap or a reference panel consisting of 379,396 individuals of 
European ancestry from the UK Biobank (supplementary table 2b).  
 
Statistical analysis 
To understand how liver and pancreas fat and volume are associated with risk of type 1 and 
type 2 diabetes, we performed a logistic regression adjusting for age, sex, height, and BMI, 
imaging centre, imaging date, and scan time. 
 
To examine if the associations are likely causal, we used inverse-variance weighted (IVW) 
two-sample MR as our main analysis (15) to estimate the effect of a 1-standard deviation 
(SD) increase in the four exposures on risk of type 1 and type 2 diabetes. In the absence of 
horizontal pleiotropy (when the genetic variants are associated with the outcome through 
pathways other than the exposure) or when horizontal pleiotropy is balanced, the IVW 
method provides an unbiased effect estimate. In addition, we performed several sensitivity 
analyses, including weighted median, MR-Egger, mode-based estimate and MR-pleiotropy 
residual sum and outlier (MR-PRESSO), to assess and account for potential horizontal 
pleiotropy. All the analyses were performed using the MendelianRandomization package in 
R (16). We used the “random” model in IVW and MR-Egger (to allow for the presence of 
heterogeneity in our instruments) and used the “penalized” parameter to penalize variants 
with heterogeneous causal estimates. We performed MR-PRESSO using the MR-PRESSO 
package in R (17). In all the above analyses, effects were aligned to the exposure-increasing 
allele reported in previously published work (9).  
 
Data and Resource Availability 
 
Type 1 diabetes (https://www.ebi.ac.uk/gwas/publications/32005708), type 2 diabetes 






Characteristics of 32,859 individuals of white British ancestry with MRI scan data from the 
UK Biobank are presented in Table 1. The mean age was 63.9 (SD 7.5) years, and 51.5% of 
participants were women. After adjusting for sex, imaging centre and scan date and time, 
liver and pancreas volume were negatively associated with age (-9.9 mL or -0.03 SD/year 
for liver volume and -0.54 mL or -0.03 SD/year for pancreas volume), pancreas fat was 
positively associated with age (0.22% or 0.026 SD/year), liver fat was positively associated 




In our observational study using data from the UK Biobank, higher liver fat was associated 
with higher risk of type 2 diabetes (odds ratio (OR) per 1 SD (5.06%) higher liver fat: 2.16 
[95% CI 2.02,2.31]); p=1e-105). The two-sample IVW MR provided evidence for a causal 
role of liver fat in risk of type 2 diabetes with an OR of 1.27 [1.08,1.49]; that is an average 
27% increased risk of type 2 diabetes per SD higher liver fat (table 2, figure 2a). Sensitivity 
analyses using the weighted median (1.29 OR), MR-Egger (1.45 OR) and mode-based 
method (1.28 OR) provided similar results. There was no evidence of heterogeneity from 
MR-Egger. Using MR-PRESSO, we found evidence for pleiotropy (pglobal test <0.001). Results 
from MR-PRESSO after outlier correction were slightly stronger (three outliers removed 
(those near APOE, GPAM, and C2orf16), OR 1.27 [1.21,1.34], supplementary tables 3 
and 4). The liver fat-increasing alleles at GPAM and C2orf16 were associated with lower risk 
of type 2 diabetes (p=0.0043 and 8.3E-5, respectively, supplementary figure 1).  
 
Observationally, higher liver fat was associated with lower risk of type 1 diabetes in the UK 
Biobank (OR 0.79 [0.65,0.96]; p=0.018). We did not find any evidence of causality between 
liver fat and risk of type 1 diabetes (OR 1.07 [0.90,1.27] per SD higher liver fat) (table 2, 
figure 2b). Results from the three sensitivity methods were similar. There was no evidence 
of heterogeneity from MR-Egger Using MR-PRESSO, we found no evidence for pleiotropy 
(pglobal test=0.34) (supplementary tables 3, supplementary figure 2).  
 
Liver volume 
Observationally, higher liver volume was associated with higher risk of type 2 diabetes (OR 
2.11 [1.96, 2.27] per 1 SD (1.38 L) higher liver volume; p=7e-90) in the UK Biobank. We did 
not find any evidence of causality between liver volume and risk of type 2 diabetes (OR 1.37 
[0.82,2.27] per SD higher liver volume) (table 2, figure 2a). However, sensitivity analyses 
using the weighted median (1.42 [1.17,1.73]) and mode-based method (1.40 [1.11,1.77]) 
provided evidence for a causal association. There was no evidence of heterogeneity from 
MR-Egger Using MR-PRESSO, we found evidence for pleiotropy (pglobal test<0.001). The 
outlier correction did not alter the inference of the results after removing six outliers (OR 1.44 
[1.24,1.69]) (supplementary tables 3 and 4, supplementary figure 3). These variants 
included those near GSTA2, GCKR, and PDIA3 (where the liver volume-increasing allele 
was associated with lower risk of type 2 diabetes), and MAU2, RSPO3 and 16:53812783 
(where the liver volume-increasing allele was associated with higher risk of type 2 diabetes.  
 
Observationally, there was no association between liver volume and type 1 diabetes (OR 
1.04 [1.00,1.09]; p=0.065) and we did not find any evidence of causality (OR 0.92 [0.67,1.27] 
per SD higher liver volume) (table 2, figure 2b). Comparison of results from the three 
sensitivity methods indicated no evidence of pleiotropy. There was no evidence of 
heterogeneity from MR-Egger. Using MR-PRESSO, we found no evidence for pleiotropy 
(pglobal test=0.15) (supplementary tables 3, supplementary figure 4).  
 
Pancreas fat 
Observationally, higher pancreatic fat was associated with higher risk of type 2 diabetes (OR 
1.42 [1.34,1.51] per SD (10.41%) higher pancreas fat; p=3e-31). However, we did not find 
any evidence of causality between pancreas fat and risk of type 2 diabetes (OR 1.02 
[0.76,1.37]) (table 2, figure 2a). Similar results were obtained using the other three 
sensitivity methods. There was no evidence for unbalanced horizontal pleiotropy from the 
MR-Egger. Using MR-PRESSO, we found evidence for pleiotropy (pglobal test<0.001). 
Removing of five outliers did not alter the inference of the results (OR 1.06 [0.87,1.29]) 
(supplementary tables 3 and 4). Among nine variants associated with pancreas fat, fat-
increasing alleles at three variants (near ABO, FAM25C, and rs4733612) were associated 
with higher risk of type 2 diabetes (p=3.9E-7, 0.036, 2.6E-5, respectively), while pancreas 
fat-increasing alleles near CEBPB, PEPD and PLEKHM3 were associated with lower risk of 
type 2 diabetes (p= 5.30E-06, 0.016, 0.0019, respectively) (supplementary figure 5).  
 
Observationally, there was no association with risk of type 1 diabetes (OR 1.08 [0.87,1.35] 
per SD higher pancreas fat; p=0.49) and we did not find any genetic evidence of causality 
(OR 1.26 [0.82,1.93]) (table 2, figure 2b). Similar results were obtained using the sensitivity 
methods. The intercept from the MR-Egger regression test provided evidence for some 
unbalanced horizontal pleiotropy The Q test did not show evidence of heterogeneity in the 
effect of pancreas fat variants on type 1 diabetes (Q-statistic 7.8). Using MR-PRESSO, we 
found evidence for pleiotropy (pglobal test=0.005) (supplementary tables 3 and 4). Removing 
one outlier did not alter the inference of the results (OR 1.47 [1.00,2.12]).  
 
Pancreas volume 
Observationally, higher pancreatic volume was associated with lower risk of type 2 diabetes 
(OR 0.73 [0.68, 0.78] per SD (0.06 L)) higher pancreas fat; p=1.31e-23). Consistently the 
two-sample IVW MR provided evidence for a causal role of pancreas volume in risk of type 2 
diabetes with an OR of 0.76 [0.62,0.94] that is an average 24% decreased risk of type 2 
diabetes per SD higher pancreas volume (table 2, figure 2a). Sensitivity analyses using the 
weighted median (0.81) and mode-based method (0.83) provided similar results. MR Egger 
yielded an OR of 0.22 [95% CI 0.11,0.43]. There was some evidence of heterogeneity from 
MR-Egger Using MR-PRESSO, we found evidence for pleiotropy (pglobal test<0.001). Results 
from MR-PRESSO after outlier correction were slightly attenuated (three outliers removed, 
OR 0.83 [0.74,0.94]) (supplementary tables 3 and 4). The variants excluded were those 
near RTL1, CTRB2 and ABO.  
 
Observationally, higher pancreas volume was associated more strongly with lower risk of 
type 1 diabetes (OR 0.42 [0.36,0.48] per SD higher pancreas volume; p=3e-33) comparing 
to type 2 diabetes. However, we did not find any evidence of causality between pancreas 
volume and risk of type 1 diabetes (OR 1.55 [0.85,2.84]) (table 2, figure 2b). Similar results 
were obtained using the sensitivity methods. The MR-Egger regression did not provide 
strong evidence for unbalanced horizontal pleiotropy. Using MR-PRESSO, we found 
evidence for pleiotropy (pglobal test<0.001). The MR estimates for type 1 diabetes did not alter 
the inference of the results after removing four outliers (OR 0.96 [0.67,1.36]) 
(supplementary tables 3 and 4).  
 









We provided genetic evidence that higher fat in the liver and lower pancreas volume were 
both causally associated with higher risk of type 2 diabetes. We did not identify evidence for 
a causal role of pancreas fat in type 2 diabetes risk or pancreas volume in type 1 diabetes 
risk. We used the largest study samples available and performed detailed investigation of 
possible violations of MR assumptions. We found evidence of pleiotropy for some variants 
and performed robust sensitivity analyses to test the assumptions of MR and corrected for it 
if violated.  
 
Liver fat. The strong genetic evidence we found for a causal role of higher liver fat in risk of 
type 2 diabetes is consistent with recent MR studies showing a causal association between 
non-alcoholic fatty liver disease or its markers (alanine aminotransferase and aspartate 
aminotransferase) and higher risk of type 2 diabetes (18; 19). Using a unique genetic 
approach, we have recently identified 36 genetic variants associated with a favourable 
adiposity (higher adiposity but a favourable metabolic phenotype and lower risk of type 2 
diabetes) and showed that lower liver fat is the key mechanism that protects against risk of 
type 2 diabetes and other related cardiometabolic diseases in spite of higher adiposity (20). 
Future work will be needed to expand MR from two-way analyses to a full causal network for 
type 2 diabetes, as the factors and co-morbidities influencing this disease, including risk for 
liver disease progression, are extraordinarily complex. The link between liver fat and type 1 
diabetes as reported in previous studies is less clear with some limited and inconsistent data 
(21). In our observational analysis, we found a negative association between liver fat and 
risk of type 1 diabetes in UK Biobank. The explanation could be that de novo lipogenesis in 
the liver falls when insulin production stops in type 1 diabetes; therefore, liver fat change is a 
consequence of insulin loss rather than a cause in type 1 diabetes. Consistently, our results 
provide no evidence for a causal role of higher liver fat in risk of type 1 diabetes.  
 
Liver volume. Although we did not find any evidence of a causal effect between liver 
volume and risk of type 2 diabetes in our main MR analysis, our sensitivity MR analyses that 
corrected for bias in our genetic instrument provided evidence for a causal association 
between higher liver volume and higher risk of type 2 diabetes. The link between higher liver 
volume and type 2 diabetes could however be a reflection of the correlation between higher 
liver fat and higher liver volume  (r=0.20 [95% CI: 0.19,0.21] in our UK Biobank data) as well 
as the correlation between obesity and liver volume (22). 
 
Pancreas fat. Observational studies of pancreatic fat provide inconsistent evidence 
regarding whether pancreatic fat is itself a driver of β‐cell dysfunction and type 2 diabetes. 
Results from the Diabetes Remission Clinical Trial (DiRECT) in the UK demonstrated that 
the remission of type 2 diabetes was associated with a major reduction in liver triglyceride 
export and a small, but significant, decrease in pancreatic fat content (23). Conversely, 
weight regain and return of diabetes were shown to be associated with increased liver and 
pancreatic fat, and re-emergence of beta cell dysfunction (24). The sequence of events 
suggest that the disease process may be triggered by deposition of ectopic fat in the 
pancreas, causing β-cell dysfunction and type 2 diabetes (25). However, other studies 
indicate no association between type 2 diabetes and pancreatic fat using either CT or 
histology at autopsy (26). All these studies are based on small numbers of selected 
individuals and our study is the first large-scale one to examine the causal effect of 
pancreatic fat in diabetes risk. Our results may be consistent with the explanation that higher 
fat in the pancreas observed in people with type 2 diabetes is secondary to disease or a 
result of a higher general obesity, but there are some caveats as discussed below. 
 
At the individual level, variants associated with higher pancreatic fat can be divided into two 
groups with opposite effect on risk of type 2 diabetes. Studies of these individual variants 
can provide further insight about the role of pancreatic fat in type 2 diabetes. The allele with 
the strongest effect on pancreatic fat (in PEPD) was associated with lower risk of type 2 
diabetes. This allele is also associated with higher body and trunk fat percentage (data from 
white British in the UK Biobank). The second pancreatic fat-increasing allele (near CEBPB) 
has been shown to be associated with lower risk of type 2 diabetes in a multi-ancestry 
analysis (27), but has not been shown to be associated with any other trait/disease. The 
third pancreatic fat-increasing allele is located in PLEKHM3 and is not associated with any 
other trait/disease. However, it is not known whether these variants lead to differential 
location of fat within the pancreas. Previous studies have shown that fat distribution varies 
significantly between the head of the pancreas and its other sections (28). This 
heterogeneity may differentially impact pancreatic function and possibly the development of 
type 2 diabetes.  
 
Pancreas volume. Our results provide the first genetic evidence that the decrease in 
pancreas volume may be causal to type 2 diabetes. Our results support the hypothesis that 
underlying mechanisms associated with reduced pancreatic volume precede diagnosis of 
type 2 diabetes. However, we did not see any evidence for a causal role of reduced 
pancreas volume in the risk of type 1 diabetes, which could be explained by two main 
factors. First, our genetic instrument for pancreas volume is based on MRI scan data of 
pancreas in adults with a mean age of 63.8 ± 7.52 years. It is possible that adult pancreas 
volume does not correlate with pancreas volume in childhood when type 1 diabetes starts. 
However, observationally, pancreas volume had a stronger association with the risk of type 
1 diabetes versus type 2 diabetes in our data. Second, we had less power to detect a causal 
association with risk of type 1 diabetes compared to type 2 diabetes (9,358 cases vs 55,005 
cases, respectively). However, the direction of effect from the MR study was not consistent 
with a tentative causal effect between reduced pancreas volume and higher risk of type 1 
diabetes. The variant with the strongest effect on pancreas volume is located near CTRB2 
and has opposing effects on risk of type 1 and 2 diabetes; the pancreas volume-increasing 
allele is associated with lower risk of type 2 diabetes and higher risk of type 1 diabetes. 
Given that the pathogenesis of type 1 and 2 diabetes are clearly different, this could signify 
that the process driving the development of the former, probably autoimmune reaction, may 
override any effect of organ size. Furthermore, there may be some variants linked to higher 
volume that may also be linked to greater likelihood of an autoimmune reaction. The minor 
allele of a correlated variant (rs7202877; r2=0.66) has been identified previously to be a risk 
factor for type 1 (29) and a protective factor for type 2 diabetes (30). The protective effect of 
the allele against type 2 diabetes has been reported to be associated with GLP-1-stimulated 
insulin secretion (31). Moreover, a recent interventional study has shown that weight gain 
and prolonged diabetes duration often lead to smaller pancreases, while weight loss 
reverses this effect, a supportive narrative of the relationship of pancreatic size and type 2 
diabetes (32), although our work adds support for pancreatic size being causal for type 2 
diabetes so opening the potential for a bidirectional relationship.  
 
Our study had some limitations. (i) We used organ volume and fat content measured in 
adulthood which could bias the association with type 1 diabetes towards the null effect. (ii) 
For some genetic variants we used as instruments, the causal genes and therefore the 
biological mechanisms are unknown which makes it difficult to test bias and pleiotropy. 
However, we used rigorous sensitivity tests that supported the main results. (iii) Our 
measurement of pancreas volume does not differentiate between endocrine and exocrine 
pancreas and more specific data are needed to understand the role of β-cell mass or 
exocrine inflammation in mechanisms that link reduced pancreas volume to higher risk of 
diabetes. (iv) The phenotyping of liver and pancreas volume/fat was performed on tractable 
measures derived from image segmentation. Although it is possible that some imaging 
artefacts are introduced in the results, any variance due to this is likely negligible given the 
size of the cohort and could not have affected our genetic instruments. (v) Using 3 point 
Dixon MRI of the pancreas, we may not have perfectly captured the pathological areas of 
pancreatic fat comparing to more sophisticated technique of MR image ‘biopsy’ method 
(MR-opsy) (28). However, MR-opsy is not practical for the very large cohorts required for 
genetic studies, the scale of which demands automated analysis and the overall impact of 
the method we used in the current study on the PDFF values and therefore the genetic 
associations would be minimal. (vi) The small difference (around 1.25-fold) of pancreas fat 
content between people with and without type 2 diabetes, and the wide range between 
individuals raises the question of sensitivity of our approach to detect a genuine difference. 
By taking a Mendelian randomization approach and using a strong instrument for pancreas 
fat and a large sample size, we had 99% power to detect any association between pancreas 
fat and risk of type 2 diabetes. However, we suggest replication of the association between 
the instrument and pancreas fat in an independent cohort would be valuable. (vii) The MRI-
derived phenotypes represent the tissue as a whole, and do not investigate within-organ 
heterogeneity, e.g. differences in the regional distribution of fatty deposits within the liver and 
pancreas, or differences in cell type or tissue sections. Also, the present set of parameters 
do not account for differences in organ shape or position. (viii) This study was conducted in 
a cohort of European ancestry. Even modest differences across populations in contributions 
of common variation to complex traits necessitates broadening the diversity of populations 
studied  (33). Therefore, our findings are only generalizable to European population. Finally, 
change in liver and pancreas fat content or volume could also be affected by 
pathophysiological mechanisms secondary to type 1 or type 2 diabetes. For example, 
subclinical exocrine inflammation of the pancreas associated with insulitis (34), as well as 
insulin deficiency and the lack of a trophic effect on pancreas exocrine tissue (3), could 
contribute to reduced pancreatic volume in type 1 diabetes, while atherosclerosis might 
cause reduction in pancreas in type 2 diabetes (35). Future MR studies investigating the role 
of type 1 and 2 diabetes on changes in these features are needed to understand the role of 
other mechanisms or if there is a mutual causal effect.  We hope other groups can validate 
or expand our findings in relevant datasets, should they exist with sufficient power. 
 
In summary, our results are in line with a causal role for higher liver fat and reduced 
pancreas volume in type 2 diabetes etiology and show consistency in sensitivity analyses. 
Given the worldwide increasing prevalence of type 1 and type 2 diabetes, better 
understanding of the underlying mechanisms involving liver and pancreas volume and fat 
content may provide new insights in preventing and treating diabetes.  
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Table 1. Study population characteristics, UK Biobank. SD: standard deviation. 




32,858 32,860 25,617 31,758 
% Female 51.5 51.5 51.2 51.4 
Age (years), mean 
(SD) 
63.9 (7.52) 63.9 (7.52) 64.2 (7.48) 63.8 (7.52) 
BMI (Kg/m2), mean 
(SD) 
26.5 (4.36) 26.5 (4.37) 26.5 (4.31) 26.5 (4.34) 
Height (cm), mean 
(SD) 
169 (9.26) 169 (9.26) 169 (9.26) 169 (9.25) 
Type 2 diabetes, n 
(%) 
1002 (3.53) 1004 (3.52) 716 (3.33) 968 (3.54) 
Type 1 diabetes, n 
(%) 
117 (0.41) 118 (0.41) 73 (0.34) 114 (0.42) 
Mean (SD) of the 
image derived 
phenotype in all 
5.06% (5)  1.38(L) (0.3)  10.41% (7.9)  0.06(L) (0.018) 




4.43% (4.7) 1.28(L) (0.25) 8.34% (6.7) 0.06(L) (0.016) 
Mean (SD) of the 
image derived 
phenotype in males 
5.73% (5.2) 1.49(L) (0.3) 12.6% (8.5) 0.06(L) (0.019) 
 
Table 2. Results of the MR study testing causal association between liver and pancreas fat/volume and type 1 and type 2 diabetes. 
Analysis OR Lower CI Upper CI P Egger intercept Heterogeneity: 
Q 
I2 Egger 
Liver fat vs. type 2 diabetes 




Weighted median 1.288 1.207 1.375 3E-14 
   
MR Egger 1.450 1.142 1.842 0.016 -0.020, p=0.19 64.1, p<0.001 0.98 
MBE 1.283 1.204 1.369 3E-14 
   
Liver fat vs. type 1 diabetes 




Weighted median 1.087 0.891 1.325 0.41 
   
MR Egger 1.025 0.772 1.360 0.87 0.006, p=0.73 11.4, p=0.18 0.98 
MBE 1.057 0.882 1.267 0.55 
   
Liver volume vs. type 2 diabetes 
IVW 1.366 0.822 2.270 0.26 
 
305.6, p<0.001 
Weighted median 1.418 1.165 1.725 0.00048 
   
MR Egger 0.959 0.320 2.873 0.94 0.028, p=0.49 289.0, p<0.001 0.70 
MBE 1.400 1.106 1.773 0.0052 
   
Liver volume vs. type 1 diabetes 




Weighted median 0.819 0.583 1.150 0.25 
   
MR Egger 0.884 0.435 1.797 0.74 0.003, p=0.90 15.8, p=0.07 0.68 
MBE 0.826 0.545 1.252 0.37 
   
Pancreas fat vs. type 2 diabetes 




Weighted median 0.956 0.810 1.129 0.60 
   
MR Egger 2.227 0.387 12.827 0.40 -0.052, p=0.40 77.5, p<0.001 0.35 
MBE 0.870 0.681 1.110 0.26 
   
Pancreas fat vs. type 1 diabetes 




Weighted median 1.656 1.120 2.449 0.011 
   
MR Egger 0.072 0.015 0.351 0.014 0.191, p=0.01 7.8, p=0.35 0.28 
MBE 1.895 0.796 4.514 0.15 
   
Pancreas volume vs. type 2 diabetes 




Weighted median 0.805 0.693 0.934 0.004 
   
MR Egger 0.220 0.112 0.433 0.00063 0.069, p=0.002 42.2, p=0.0001 0.00 
MBE 0.825 0.639 1.066 0.14 
   
Pancreas volume vs. type 1 diabetes 




Weighted median 1.159 0.735 1.826 0.53 
   
MR Egger 13.425 1.159 155.453 0.057 -0.121, p=0.10 70.8, p<0.001 0.35 
MBE 0.871 0.429 1.771 0.70 
   
The odds ratio (OR) are per 1 standard deviation higher liver and pancreas fat/volume. CI: 95% confidence interval; IVW: inverse-variance 
weighted; MBE: mode-based estimate; MR: Mendelian randomisation.
Figures 
 
Figure 1. A: Relationship between liver and pancreas fat and volume and age within the UK 
Biobank. Each trait is standardised, so that the y axis represents standard deviations, after 
adjustment for imaging centre and date. The trend is smoothed using a generalised additive 
model with smoothing splines for visualisation purposes. B: The density plots of liver and 
pancreas fat and volume in type 1 and type 2 diabetes cases and controls within the UK 
Biobank study. 
 
Figure 2. The inverse-variance weighted, weighted median, Egger and mode-based two-
sample Mendelian randomisation (MR) results for (A) type 2 diabetes and (B) type 1 
diabetes. Only 16 of the 17 pancreas volume SNPs were present in each GWAS. The error 
bars represent the 95% confidence intervals (CI) of the MR estimates in odds ratio (OR) per 
standard deviation change in genetically determined liver and pancreas fat/volume. SNP, 
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